Autism - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Autism - Pipeline Review, H2 2015’, provides an overview of the Autism’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Autism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Autism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Autism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Autism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Autism Overview 10
Therapeutics Development 11
Pipeline Products for Autism - Overview 11
Pipeline Products for Autism - Comparative Analysis 12
Autism - Therapeutics under Development by Companies 13
Autism - Therapeutics under Investigation by Universities/Institutes 15
Autism - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Autism - Products under Development by Companies 20
Autism - Products under Investigation by Universities/Institutes 22
Autism - Companies Involved in Therapeutics Development 23
Addex Therapeutics Ltd 23
BioCrea GmbH 24
BrainStorm Cell Therapeutics Inc. 25
Cellceutix Corporation 26
Confluence Pharmaceuticals LLC 27
Curemark, LLC 28
Egenix, Inc. 29
F. Hoffmann-La Roche Ltd. 30
Heptares Therapeutics Limited 31
Intra-Cellular Therapies, Inc. 32
MedDay 33
Merz Pharma GmbH & Co. KgaA 34
Mnemosyne Pharmaceuticals, Inc. 35
Omeros Corporation 36
Otsuka Holdings Co., Ltd. 37
Retrophin Inc. 38
Reviva Pharmaceuticals Inc. 39
Saniona AB 40
Sumitomo Dainippon Pharma Co., Ltd. 41
Autism - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
acamprosate calcium - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ADX-71441 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ADX-88178 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
aripiprazole - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
aripiprazole - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
carbetocin - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CM-AT - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CN-2097 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Drug for Autism - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
HTL-14242 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ITI-007 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
KM-391 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
lurasidone hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MD-1103 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
memantine hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
oxytocin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RG-7314 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
RO-5285119 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
RP-5063 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecule to Modulate GABRA5 Receptor for CNS Disorders - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Target GPR63 for Autism - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
suramin hexasodium - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
VU-0410120 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Autism - Recent Pipeline Updates 92
Autism - Dormant Projects 123
Autism - Discontinued Products 124
Autism - Product Development Milestones 125
Featured News & Press Releases 125
Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole 125
Jun 10, 2015: Clinical trial launched to assess safety and efficacy of autism drug treatment 125
May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism 126
Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment 127
Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism 127
Mar 13, 2013: Researchers Use Old Drug Treatment To Correct Autism Symptoms In Mouse Model 127
Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors 128
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 130
Disclaimer 131
List Of Tables
Number of Products under Development for Autism, H2 2015 11
Number of Products under Development for Autism - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Comparative Analysis by Unknown Stage Development, H2 2015 19
Products under Development by Companies, H2 2015 20
Products under Development by Companies, H2 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2015 22
Autism - Pipeline by Addex Therapeutics Ltd, H2 2015 23
Autism - Pipeline by BioCrea GmbH, H2 2015 24
Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2015 25
Autism - Pipeline by Cellceutix Corporation, H2 2015 26
Autism - Pipeline by Confluence Pharmaceuticals LLC, H2 2015 27
Autism - Pipeline by Curemark, LLC, H2 2015 28
Autism - Pipeline by Egenix, Inc., H2 2015 29
Autism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 30
Autism - Pipeline by Heptares Therapeutics Limited, H2 2015 31
Autism - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 32
Autism - Pipeline by MedDay, H2 2015 33
Autism - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015 34
Autism - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2015 35
Autism - Pipeline by Omeros Corporation, H2 2015 36
Autism - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 37
Autism - Pipeline by Retrophin Inc., H2 2015 38
Autism - Pipeline by Reviva Pharmaceuticals Inc., H2 2015 39
Autism - Pipeline by Saniona AB, H2 2015 40
Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 41
Assessment by Monotherapy Products, H2 2015 42
Assessment by Combination Products, H2 2015 43
Number of Products by Stage and Target, H2 2015 45
Number of Products by Stage and Mechanism of Action, H2 2015 47
Number of Products by Stage and Route of Administration, H2 2015 49
Number of Products by Stage and Molecule Type, H2 2015 51
Autism Therapeutics - Recent Pipeline Updates, H2 2015 92
Autism - Dormant Projects, H2 2015 123
Autism - Discontinued Products, H2 2015 124
List Of Figures
List of Figures
Number of Products under Development for Autism, H2 2015 11
Number of Products under Development for Autism - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Products, H2 2015 18
Assessment by Monotherapy Products, H2 2015 42
Number of Products by Top 10 Targets, H2 2015 44
Number of Products by Stage and Top 10 Targets, H2 2015 44
Number of Products by Top 10 Mechanism of Actions, H2 2015 46
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 46
Number of Products by Routes of Administration, H2 2015 48
Number of Products by Stage and Routes of Administration, H2 2015 48
Number of Products by Molecule Types, H2 2015 50
Number of Products by Stage and Molecule Types, H2 2015 50
